Search

Your search keyword '"Oshige, Tatsuhiro"' showing total 19 results
Start Over Author "Oshige, Tatsuhiro"
19 results on '"Oshige, Tatsuhiro"'

5. Successful treatment of PR3-ANCA-positive interstitial pneumonia with a moderate dose of glucocorticoid and rituximab.

Author

Higashida-Konishi, Misako, Akiyama, Mitsuhiro, Hama, Satoshi, Oshige, Tatsuhiro, Izumi, Keisuke, Oshima, Hisaji, and Okano, Yutaka

Subjects
PULMONARY fibrosis, IDIOPATHIC interstitial pneumonias, RITUXIMAB, TREATMENT effectiveness, POSITRON emission tomography computed tomography, GLUCOCORTICOIDS, ANTINEUTROPHIL cytoplasmic antibodies
Published
2024
Full Text
View/download PDF

12. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis

Author

Hama, Satoshi, primary, Akiyama, Mitsuhiro, additional, Higashida-Konishi, Misako, additional, Oshige, Tatsuhiro, additional, Takei, Hiroshi, additional, Izumi, Keisuke, additional, Oshima, Hisaji, additional, and Okano, Yutaka, additional

Published
2022
Full Text
View/download PDF

14. Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.

Author

Hama, Satoshi, Akiyama, Mitsuhiro, Higashida-Konishi, Misako, Oshige, Tatsuhiro, Takei, Hiroshi, Izumi, Keisuke, Oshima, Hisaji, and Okano, Yutaka

Subjects
DERMATOMYOSITIS, INTERSTITIAL lung diseases, TREATMENT effectiveness, CONNECTIVE tissue diseases, PLASMA exchange (Therapeutics), MEDICAL research, INFORMED consent (Medical law)
Published
2023
Full Text
View/download PDF

18. Deep remission within 12 months prevents renal flare and damage accrual in lupus nephritis.

Author

Kikuchi J, Hanaoka H, Saito S, Oshige T, Hiramoto K, Takeuchi T, and Kaneko Y

Subjects
Humans, Infant, Treatment Outcome, Immunosuppressive Agents, Retrospective Studies, Kidney, Remission Induction, Lupus Nephritis drug therapy
Abstract

Objectives: To evaluate the significance of achieving deep remission by induction therapy in lupus nephritis (LN) patients., Methods: We assessed consecutive patients undergoing induction therapy for active LN. Achievement of complete renal response (CR) was defined as a urine protein creatinine ratio (UPCR) ≤0.5 g/gCr, and deep remission (DR) was defined as a UPCR ≤0.15 g/gCr with stabilisation of serum creatinine levels assessed every 2-3 months. We compared renal flare and damage accrual rates among patients with CR, CR without DR, and DR at 3, 6, and 12 months and later., Results: Fifty-nine Asian patients were enrolled, and the median observation period was 48.6 months. Of these, 55 patients achieved CR, and 33 achieved DR within 12 months of receiving induction therapy. The patients with DR within 12 months experienced a significantly lower rate of subsequent renal flare (p<0.001) and damage accrual (p=0.046) than those without CR, those with DR after 12 months, and those with no DR but CR within 12 months. In addition, younger age, shorter disease duration, lower urine protein at baseline, and earlier renal response were associated with DR within 12 months., Conclusions: Achievement of DR within 12 months after induction therapy should be a treatment target for active LN, as it has implications for preventing renal flare and damage accrual.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results